2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4ab,This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HCT early in the management of eligible patients with high-risk disease. Advanced stage, large-cell transformation, relapsed or refractory disease following systemic treatment, and N3-stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post-transplant outcomes and survival.31:T4ed,AbstractThis manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo‐HCT) for cutaneous T‐cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post‐transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo‐HCT early in the management of eligible patients with high‐risk disease. Advanced stage, large‐cell transformation, relapsed or refractory disease following systemic treatment, and N3‐stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post‐transplant outcomes and survival.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Allogeneic Hematopoietic Cell Transplantation: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Allogeneic Hematopoietic Cell Transplantation (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Allogeneic%20Hematopoietic%20Cell%20Transplantation\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Allogeneic Hematopoietic Cell Transplantation\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Allogeneic%20Hematopoietic%20Cell%20Transplantation\"}]}}"}}]],["$","$L2f",null,{"title":"Allogeneic Hematopoietic Cell Transplantation: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Allogeneic Hematopoietic Cell Transplantation — concise summaries and practical next steps.","papers":[{"doi":"10.1097/moh.0000000000000948","pmid":"42593279","title":"Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignancies","journal_title":"Current Opinion in Hematology","journal_issn":"1065-6251","published_at":"2026-08-13T00:00:00.000Z","url":"https://doi.org/10.1097/moh.0000000000000948","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-22T06:53:31.683Z","updated_at":"2026-08-22T06:53:31.683Z","tags":[{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"brand","value":"Xospata","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"condition","value":"Myelodysplastic Syndromes","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"generic","value":"gilteritinib","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"generic","value":"sorafenib","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"FLT3 Inhibitor","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"IDH Inhibitor","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"Menin Inhibitor","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"warning","value":"Sample size tag was omitted as this is a review article with no single study population.","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"warning","value":"Sex distribution of patient populations across reviewed trials is not reported in the abstract; sex tag was omitted.","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the shift toward MRD-guided targeted strategies described in the review, but most supporting data come from individual trials cited within, not from this review itself.","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"warning","value":"This is a narrative/critical review, not a primary study or meta-analysis — evidence levels vary by agent discussed within the paper.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates the evidence for post-allogeneic HCT maintenance therapy to prevent relapse in AML and MDS, covering FLT3 inhibitors, IDH inhibitors, menin inhibitors, and hypomethylating agents, with attention to MRD-guided patient selection strategies.","key_result":"FLT3 inhibitors (sorafenib, gilteritinib) have the strongest evidence from randomized trials in FLT3-ITD AML; the MORPHO trial showed MRD status identifies patients most likely to benefit from gilteritinib. IDH and menin inhibitors are promising but lack randomized data. Hypomethylating agent maintenance yielded inconsistent results, with evidence favoring MRD-triggered preemptive therapy over broad application.","limitations":"No large, adequately powered HCT-specific randomized trials exist for most agents; MRD endpoints lack standardization across studies; evidence for IDH inhibitors and menin inhibitors is limited to non-randomized data.","practice_takeaway":"For FLT3-ITD AML post-HCT, consider sorafenib or gilteritinib maintenance, using MRD status to guide patient selection. For patients without actionable mutations, MRD-triggered preemptive therapy is preferred over routine hypomethylating agent maintenance."}},{"doi":"10.1182/blood.2025029805","pmid":"42378229","title":"CD4+CD25+FOXP3+ regulatory T cells to protect against graft-versus-host disease","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-06-30T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025029805","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-14T06:23:25.060Z","updated_at":"2026-09-14T06:23:25.060Z","tags":[{"paper_doi":"10.1182/blood.2025029805","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"condition","value":"Bone Marrow Failure","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"condition","value":"Graft-Versus-Host Disease","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"condition","value":"Hematological Malignancies","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"generic","value":"CD4+CD25+FoxP3+ regulatory T cells","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"modality","value":"Regulatory T Cell Therapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"warning","value":"No sample size is applicable as this is a review article with no original patient cohort.","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"warning","value":"The 'impact_flag' of practice_changing reflects the translational significance described by the authors, but direct evidence of changed practice standards requires verification against primary trial publications.","value_numeric":null},{"paper_doi":"10.1182/blood.2025029805","tag_type":"warning","value":"This is a narrative review, not a systematic review or meta-analysis; the scope and selection of included studies may reflect author perspective.","value_numeric":null}],"summaries":{"what_studied":"This review covers the history, preclinical research, and clinical translation of CD4+CD25+FoxP3+ regulatory T cells (Tregs) as a strategy to prevent graft-versus-host disease (GVHD) in the setting of allogeneic hematopoietic cell transplantation (HCT).","key_result":"Treg-based approaches have been successfully translated from preclinical models to clinical use, offering a pathway to reduce GVHD and transplant-related nonrelapse mortality — potentially expanding allogeneic HCT eligibility to patients with a broader range of immune-mediated disorders.","limitations":"As a review article, no new primary data or controlled trial results are presented; conclusions depend on the quality and heterogeneity of the underlying studies reviewed.","practice_takeaway":"Treg-based cellular therapy represents a clinically viable strategy to mitigate GVHD after allogeneic HCT. Clinicians should monitor emerging Treg trial data, as this approach may eventually lower the risk threshold for offering HCT to patients with non-malignant immune-mediated conditions."}},{"doi":"10.1200/jco-26-00113","pmid":"42348822","title":"Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-06-25T00:00:00.000Z","url":"https://doi.org/10.1200/jco-26-00113","source_score":60,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-19T06:28:58.803Z","updated_at":"2026-08-19T06:28:58.803Z","tags":[{"paper_doi":"10.1200/jco-26-00113","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"condition","value":"Graft-versus-Host Disease","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"condition","value":"Hematologic Malignancies","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"condition","value":"Leukemia Relapse","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"modality","value":"Donor Lymphocyte Infusion","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"sample_size","value":"n=533","value_numeric":533},{"paper_doi":"10.1200/jco-26-00113","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"study_design","value":"Retrospective Multicenter Cohort Study","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"warning","value":"Sex distribution and age breakdown are not reported in the abstract; sex and age_group tags reflect reasonable assumptions for a mixed hematologic malignancy cohort.","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"warning","value":"The phasing tool uses HLA frequency data from ~5 million individuals; accuracy may vary across underrepresented ethnic populations.","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"warning","value":"The sample of 533 represents relapses, not total transplant recipients — the denominator for calculating overall HLA loss incidence across all transplants is not provided.","value_numeric":null},{"paper_doi":"10.1200/jco-26-00113","tag_type":"warning","value":"The study is retrospective and multicenter; heterogeneity in treatment protocols across 27 centers may affect outcome comparability.","value_numeric":null}],"summaries":{"what_studied":"This multicenter study analyzed 533 relapses of hematologic malignancies after allogeneic HCT across 27 centers worldwide, evaluating the frequency and determinants of genomic HLA loss as an immune evasion mechanism, and its impact on post-relapse outcomes across different donor types.","key_result":"HLA loss occurred in 15.6% of all relapses, with marked variation by donor type: 28.7% haploidentical family donors, 7.2% unrelated adult donors, and 2.7% cord blood donors (P < .0001). When HLA mismatches were concentrated on the same haplotype, HLA loss risk was 27.6% vs. 5.4% when mismatches spanned different haplotypes (P < .0001). HLA loss abrogated the efficacy of original donor lymphocyte infusions, and second allo-HCT from a different donor conferred a significant survival advantage.","limitations":"Retrospective multicenter design introduces selection and reporting biases. Post-relapse treatment data and survival outcomes are not reported with full detail in the abstract. The phasing tool relies on population-level HLA frequency data (~5 million individuals), which may not equally represent all ethnic groups.","practice_takeaway":"At relapse after allo-HCT, routinely assess for HLA loss using NGS — especially in haploidentical transplants — as it predicts failure of donor lymphocyte infusions and guides the decision to pursue a second transplant from a different donor. Use the web-based phasing tool at donor selection to identify high-risk HLA mismatch configurations (same-haplotype clustering) and weigh alternative donors accordingly."}},{"doi":"10.1038/s41409-026-02958-2","pmid":"42342969","title":"Reconsidering the role of bone marrow as a graft source in haploidentical allogeneic hematopoietic cell transplantation","journal_title":"Bone Marrow Transplantation","journal_issn":"0268-3369","published_at":"2026-06-24T00:00:00.000Z","url":"https://doi.org/10.1038/s41409-026-02958-2","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-28T13:27:09.326Z","updated_at":"2026-06-28T13:27:09.326Z","tags":[{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"condition","value":"Graft-Versus-Host Disease","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"condition","value":"Secondary Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"modality","value":"Post-Transplant Cyclophosphamide","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"sample_size","value":"n=554","value_numeric":554},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"study_design","value":"Correspondence / Commentary","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"warning","value":"Full text was not available; specific arguments and cited evidence within the correspondence could not be fully verified.","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"warning","value":"Study design tag reflects the nature of this publication (editorial correspondence), not the referenced primary study.","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02958-2","tag_type":"warning","value":"This is a correspondence/commentary with no original patient data — the n=554 sample size refers to the Nagler et al. study being discussed, not a study conducted by these authors.","value_numeric":null}],"summaries":{"what_studied":"This correspondence comments on a retrospective registry study (n=554) by Nagler et al. comparing peripheral blood stem cells (PBSC) vs. bone marrow (BM) as graft sources for non-T-depleted haploidentical HCT with post-transplant cyclophosphamide (PTCy) in secondary AML in first complete remission. The authors highlight practical, logistical, and donor safety considerations favoring PBSC.","key_result":"The referenced Nagler et al. study found no significant differences in survival, relapse risk, or GVHD between PBSC and BM in this setting; the correspondence authors argue additional practical and safety factors further support PBSC as the preferred graft source.","limitations":"This is a correspondence/commentary, not a primary study — no original data or statistical analyses are presented. The underlying registry study is retrospective and subject to selection bias. Full text of the correspondence is not available, limiting assessment of the specific arguments made.","practice_takeaway":"When selecting a graft source for haploidentical HCT with PTCy in secondary AML, PBSC and BM appear comparably effective by survival metrics, but donor safety and logistical factors may tip the balance toward PBSC. Clinicians should weigh both outcomes data and operational considerations when counseling donors and planning transplants."}},{"doi":"10.1038/s41409-026-02919-9","pmid":"42203900","title":"The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy","journal_title":"Bone Marrow Transplantation","journal_issn":"0268-3369","published_at":"2026-05-27T00:00:00.000Z","url":"https://doi.org/10.1038/s41409-026-02919-9","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-01T13:39:29.606Z","updated_at":"2026-06-01T13:39:29.606Z","tags":[{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"condition","value":"Acute Lymphoblastic Leukemia","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"condition","value":"Autoimmune Disease","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"condition","value":"Hematologic Malignancies","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"condition","value":"Lymphoma","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"condition","value":"Multiple Myeloma","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"condition","value":"Non-Malignant Disorders","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"modality","value":"Autologous Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"modality","value":"CAR-T Cell Therapy","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"sample_size","value":"n=43791","value_numeric":43791},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"study_design","value":"Registry Survey / Activity Report","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"warning","value":"Study design labelled as 'Registry Survey / Activity Report'; it does not fit neatly into standard RCT-based evidence hierarchy — level of evidence assigned as 4 (case series/registry).","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"warning","value":"The 'one million HCTs' milestone counts cumulative procedures since 1990, not unique patients.","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02919-9","tag_type":"warning","value":"This is a registry activity report, not a clinical outcomes study — no survival, response, or toxicity data are reported.","value_numeric":null}],"summaries":{"what_studied":"The 2024 EBMT annual activity survey tracked hematopoietic cell transplantation (HCT) and CAR-T therapy trends across 688 centres in 53 countries, covering 43,791 patients who received 47,204 HCTs and 6,082 CAR-T treatments.","key_result":"In 2024, allogeneic HCT reached its highest annual total (21,023; +2.6% vs. 2023), while autologous HCT fell (-3.9%; 26,181 total). CAR-T therapy grew sharply (+24.5% to 6,082 patients), with lymphomas the top CAR-T indication (70%), followed by multiple myeloma (18%) and ALL (8%). Autoimmune disease CAR-T use surged +67%. Cord blood use continued to decline (-6.2%), and paediatric HCT decreased slightly (-1.7%).","limitations":"Registry-based survey data rely on voluntary centre reporting, so completeness and accuracy vary by country. Outcomes data (survival, toxicity) are not captured in this activity report.","practice_takeaway":"Allogeneic HCT and CAR-T therapy are both growing, with CAR-T now exceeding 20,000 cumulative patients since 2018 — clinicians should expect continued expansion, especially in autoimmune indications. Cord blood as a stem cell source is declining and may become less available for future patients."}},{"doi":"10.1182/blood.2025030059","pmid":"41802111","title":"Immune-mediated side effects of cancer immunotherapies","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-03-09T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025030059","source_score":12,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-20T13:25:06.776Z","updated_at":"2026-06-20T13:25:06.776Z","tags":[{"paper_doi":"10.1182/blood.2025030059","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"condition","value":"Cytokine Release Syndrome","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"condition","value":"Graft-Versus-Host Disease","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"condition","value":"Hematologic Malignancies","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"condition","value":"Hemophagocytic Lymphohistiocytosis","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"condition","value":"Immune Effector Cell-Associated Neurotoxicity Syndrome","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"condition","value":"Immune-Related Adverse Events","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"modality","value":"CAR T-Cell Therapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"warning","value":"Sex of study populations is not reported as this is a review article covering multiple conditions and trials.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"warning","value":"The 'impact_flag' of practice_changing reflects the breadth of clinical guidance synthesized, not a single trial result.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030059","tag_type":"warning","value":"This is a narrative review published in Blood; no original patient-level data or meta-analytic statistics are reported. Conclusions are expert synthesis, not graded evidence.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates the biological mechanisms, pathophysiology, and management strategies for immune-mediated toxicities arising from cancer immunotherapies — including allogeneic HCT (acute GVHD), CAR T-cell therapies (CRS, ICANS, IEC-HS, IEC-HT, LICAST), and immune checkpoint inhibitors (irAEs) — with a focus on the roles of myeloid and T cells, including tissue-resident T cells.","key_result":"Shared pathophysiologic mechanisms across acute GVHD, CAR T-cell toxicities, and irAEs — particularly involving myeloid and tissue-resident T cell dysregulation — provide a rationale for overlapping therapeutic strategies; approved, investigational, and potential future therapies targeting these commonalities are summarized.","limitations":"As a narrative review, it does not report original clinical trial data or pooled statistics. Evidence synthesis is qualitative, and the strength of recommendations for emerging therapies is not formally graded.","practice_takeaway":"Clinicians managing immune-mediated toxicities from GVHD, CAR T-cell therapy, or checkpoint inhibitors should recognize shared immune mechanisms that may allow cross-applicable treatment strategies. Awareness of both established and investigational therapies targeting myeloid and T-cell pathways can inform management of these overlapping toxicity syndromes."}},{"doi":"10.1182/blood.2025031858","pmid":"41785374","title":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-03-05T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025031858","source_score":6,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-02T13:27:32.032Z","updated_at":"2026-06-02T13:27:32.032Z","tags":[{"paper_doi":"10.1182/blood.2025031858","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"brand","value":"Briquilimab","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"condition","value":"Myelodysplastic Syndrome","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"generic","value":"fludarabine","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"modality","value":"Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"sample_size","value":"n=32","value_numeric":32},{"paper_doi":"10.1182/blood.2025031858","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"study_design","value":"Phase 1 Clinical Trial","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"warning","value":"Briquilimab does not yet have a nonproprietary INN-style generic name confirmed in RxNorm; listed under brand name only.","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"warning","value":"Level of evidence assigned as 3 (non-randomized phase 1 trial with proof-of-concept design); no randomized comparator exists in this study.","value_numeric":null},{"paper_doi":"10.1182/blood.2025031858","tag_type":"warning","value":"The AML-in-relapse subgroup (n=3) is too small to interpret efficacy results and should be treated as anecdotal.","value_numeric":null}],"summaries":{"what_studied":"Phase 1 trial evaluating briquilimab (anti-CD117 monoclonal antibody) added to nonmyeloablative fludarabine/TBI conditioning in adults ≥median age 70 years with high-risk AML or MDS undergoing matched donor allogeneic HCT (NCT04429191).","key_result":"No infusion reactions, dose-limiting toxicities, or primary graft failures were observed (n=32). In AML-in-CR patients (n=13), 1-year EFS was 69.2% and OS was 75%; in MDS patients (n=16), 1-year EFS was 53.8% and OS was 76.4%. Briquilimab depleted AML/MDS hematopoietic stem and progenitor cells by a mean of 62.4% ± 22.7%, with a resultant ~3-fold rise in serum SCF.","limitations":"- Small phase 1 sample (n=32), limiting power to draw efficacy conclusions.\n- No control arm; comparisons to standard conditioning are not possible.\n- Only 3 patients had active AML in relapse, too few for meaningful efficacy assessment in that subgroup.","practice_takeaway":"Briquilimab combined with nonmyeloablative Flu/TBI appears safe and feasible as HCT conditioning in older adults with AML/MDS, with no graft failures and manageable toxicity. Larger trials are needed before this approach can be adopted in routine practice."}},{"doi":"10.1182/blood.2025030823","pmid":"41746780","title":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-02-26T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025030823","source_score":25,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:51:13.314Z","updated_at":"2026-05-07T22:51:13.314Z","tags":[{"paper_doi":"10.1182/blood.2025030823","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"condition","value":"Graft-Versus-Host Disease","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"condition","value":"Hematologic Malignancy","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"modality","value":"GVHD Prophylaxis","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"warning","value":"No specific patient sample size is applicable to this review article.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"warning","value":"The paper is published with a future date (2026-02-26) relative to today; this appears to be an ahead-of-print or early access publication.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030823","tag_type":"warning","value":"This is an expert narrative review with illustrative case vignettes, not a systematic review or RCT — recommendations reflect author opinion synthesized from varied data sources.","value_numeric":null}],"summaries":{"limitations":"This is a narrative/expert review with case vignettes, not a systematic review or meta-analysis; recommendations reflect author interpretation of heterogeneous trial and retrospective data rather than a single high-quality RCT.","what_studied":"This review examines how to prioritize hematopoietic cell transplant (HCT) donors in the era of posttransplant cyclophosphamide (PTCy)-based GVHD prevention, covering HLA and non-HLA donor selection parameters, disease-specific considerations, and strategies to expand donor availability in adult allogeneic HCT.","key_result":"Recent clinical trials and retrospective studies show that survival outcomes after HLA-mismatched donor HCT (haploidentical or mismatched unrelated) with PTCy approach those of HLA-matched donor recipients, challenging the traditional hierarchical donor selection model.","practice_takeaway":"In the PTCy era, HLA-mismatched donors—including haploidentical relatives and mismatched unrelated donors—are now viable first-tier options and should not be deferred automatically. Clinicians should weigh both HLA and non-HLA factors (e.g., donor age, cytomegalovirus status, disease-specific needs) when selecting among multiple available donors."}},{"doi":"10.1111/jdv.70042","pmid":"41031482","title":"Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee","journal_title":"Journal of the European Academy of Dermatology and Venereology","journal_issn":"0926-9959","published_at":"2025-10-01T00:00:00.000Z","url":"https://doi.org/10.1111/jdv.70042","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-05","doi":"10.1111/jdv.70042","days":"7","issn":"0926-9959","rank":"10","field":"Clinical Medicine","score":"1","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jdv.70042","title":"Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","methods":"","results":"","abstract":"$30","keywords":["Sézary syndrome","allogeneic transplantation","cutaneous T‐cell","lymphomas","mycosis fungoides","skin cancer"],"pubmed_id":"41031482","conclusions":"","publication_date":"2025-10-01T00:00:00"},"crossref":{"DOI":"10.1111/jdv.70042","URL":"https://doi.org/10.1111/jdv.70042","ISSN":["0926-9959","1468-3083"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.70042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee"],"author":[{"given":"Gandhi","family":"Damaj","sequence":"first","affiliation":[{"name":"Caen University Hospital Hematology Institute, Normandy University, School of Medicine Caen France"}]},{"given":"Adèle","family":"de Masson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Saint‐Louis Hospital, AP‐HP, National Reference Center for Cutaneous Lymphomas, Institut du Cancer AP‐HP Nord, Université Paris Cité Paris France"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"Department of Medicine V University of Heidelberg Heidelberg Germany"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Chair of the EBMT Lymphoma Working Party, Bone Marrow Transplantation Program, Department of Internal Medicine American University of Beirut Beirut Lebanon"}]},{"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]},{"given":"Rafael F.","family":"Duarte","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain"}]},{"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham Nottingham UK"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[{"name":"University Institute and Clinic for Immuno‐Dermatology, Medical Faculty Johannes Kepler University, Secretary of the EORTC Cutaneous Lymphoma Tumor Group Linz Austria"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Service d'Hématologie Adultes, Institut Necker Enfants Malades, Unité INSERM U1153, Hôpital Universitaire Necker‐Enfants Malades, AP‐HP, Université Paris Cité and Imagine Institute Paris France"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[{"name":"Secretary of the EBMT LWP, Department of Hematology University College London Hospital London UK"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute University of Medicine and Pharmacy Carol Davila Bucharest Romania"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy Clermont‐Ferrand University Hospital, UCA, EA7453 Chelter CIC‐1405 Clermont‐Ferrand France"}]},{"given":"Wojiech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Maria Sklodowska Curie National Research Institute of Oncology Krakow Poland"}]},{"given":"Imke E.","family":"Karsten","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]},{"given":"Stéphanie Nguyen","family":"Quoc","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cellular Therapies Sorbonne University Pitié‐Salpêtrière Hospital Paris France"}]},{"given":"Yasmina","family":"Serroukh","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC Cancer Institute, University Medical Center Rotterdam Rotterdam The Netherlands"}]},{"given":"Federico","family":"Stella","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale Dei Tumori Milano, University of Milano Milan Italy"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Hospital Goettingen Goettingen Germany"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Institut Català d'Oncologia – L'hospitalet, Institut de Recerca Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Barcelona Spain"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[{"name":"Department of Dermatology National and Kapodistrian University of Athens, Attikon University Hospital Athens Greece"}]},{"given":"Pablo L.","family":"Ortiz‐Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology Institute i+12, Hospital 12 de Octubre Medical School University Complutense Madrid Spain"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Co‐Chair of the Practice Harmonisation and Guidelines Committee of EBMT and Chair of the CTIWP of the EBMT. Hematology and BMT Unit IRCCS San Raffaele Hospital Milan Italy"}]},{"given":"Isabel","family":"Sánchez‐Ortega","sequence":"additional","affiliation":[{"name":"Secretary of the Practice Harmonisation and Guidelines Committee of EBMT; EBMT Medical Officer, Executive Office Barcelona Spain"}]},{"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"University Hospital Birmingham and University of Birmingham Birmingham UK"}]},{"given":"Ibrahim","family":"Yakoub‐Agha","sequence":"additional","affiliation":[{"name":"Chair of the EBMT Practice Harmonisation and Guidelines Committee; Lille University Hospital, Lille University, INSERM U1286, Infinite Lille France"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"Co‐Chair of the Practice Harmonisation and Guidelines Committee of the EBMT; Hematology and BMT Centre, ASST Fatebenefratelli‐Sacco University of Milan Milan Italy"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-01T10:01:09Z","timestamp":1759312869000,"date-parts":[[2025,10,1]]},"indexed":{"date-time":"2025-10-02T00:41:49Z","timestamp":1759365709081,"date-parts":[[2025,10,2]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000,"date-parts":[[2025,10,1]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.70042"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-04-10"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-07-11"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-01"}],"deposited":{"date-time":"2025-10-01T10:01:10Z","timestamp":1759312870000,"date-parts":[[2025,10,1]]},"issn-type":[{"type":"print","value":"0926-9959"},{"type":"electronic","value":"1468-3083"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/bjd.19644","key":"e_1_2_15_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers12102921","key":"e_1_2_15_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2018-11-881268","key":"e_1_2_15_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17258","key":"e_1_2_15_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.10.006","key":"e_1_2_15_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2011.39.8065","key":"e_1_2_15_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdt480","key":"e_1_2_15_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.21449","key":"e_1_2_15_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00277-014-2121-1","key":"e_1_2_15_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(18)30379-6","key":"e_1_2_15_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)31266-7","key":"e_1_2_15_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2015.61.7142","key":"e_1_2_15_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18541","key":"e_1_2_15_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00329-X","key":"e_1_2_15_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-020-01197-3","key":"e_1_2_15_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2010.29.3241","key":"e_1_2_15_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2019.08.019","key":"e_1_2_15_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/14737140.2024.2305356","key":"e_1_2_15_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2023.113343","key":"e_1_2_15_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtct.2024.08.020","key":"e_1_2_15_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-023-01958-w","key":"e_1_2_15_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2021012057","key":"e_1_2_15_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.10.014","key":"e_1_2_15_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2010.28.9066","key":"e_1_2_15_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2014.57.5597","key":"e_1_2_15_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2024.102679","key":"e_1_2_15_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s12185-024-03753-9","key":"e_1_2_15_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2016.67.8250","key":"e_1_2_15_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2007-03-055749","key":"e_1_2_15_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2009.27.7665","key":"e_1_2_15_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/PAT.0000000000000166","key":"e_1_2_15_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2013.09.007","key":"e_1_2_15_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clml.2017.11.004","key":"e_1_2_15_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2020.1790555","key":"e_1_2_15_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-2950","key":"e_1_2_15_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/bloodadvances.2020001627","key":"e_1_2_15_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-024-02236-z","key":"e_1_2_15_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.3007420","key":"e_1_2_15_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18806","key":"e_1_2_15_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18215","key":"e_1_2_15_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19220","key":"e_1_2_15_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2009.25.8301","key":"e_1_2_15_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2024.11.011","key":"e_1_2_15_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2019.1658106","key":"e_1_2_15_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-023-02122-0","key":"e_1_2_15_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_47_1","year":"2024","issue":null,"author":"Onida F","volume":"59","first-page":null,"unstructured":null,"article-title":"Allogeneic hematopoietic cell transplantation in patients with advanced mycosis fungoides and Sézary syndrome: a retrospective analysis including 63 consecutive patients with long‐term median follow‐up","journal-title":"Bone Marrow Transplant","doi-asserted-by":null},{"DOI":"10.1182/bloodadvances.2021005899","key":"e_1_2_15_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtct.2022.11.028","key":"e_1_2_15_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2018.06.026","key":"e_1_2_15_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2006.08.0952","key":"e_1_2_15_51_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.02408","key":"e_1_2_15_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2991/chi.k.210529.001","key":"e_1_2_15_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/ajh.27531","key":"e_1_2_15_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/09636897241270401","key":"e_1_2_15_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2024.2376164","key":"e_1_2_15_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-018-0400-5","key":"e_1_2_15_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2352-3026(19)30256-X","key":"e_1_2_15_58_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.15661","key":"e_1_2_15_59_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clml.2020.06.020","key":"e_1_2_15_60_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00508-4","key":"e_1_2_15_61_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jdv.70042"],"article-number":"jdv.70042","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"reference-count":60,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10]]},"references-count":60,"short-container-title":["Acad Dermatol Venereol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jdv.70042","is_oa":true,"title":"Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee","updated":"2025-10-06T00:09:52+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.70042","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.70042","url_for_landing_page":"https://doi.org/10.1111/jdv.70042"}}},"created_at":"2025-10-10T09:56:52.931Z","updated_at":"2025-10-10T09:56:52.931Z","tags":[{"paper_doi":"10.1111/jdv.70042","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Sezary Syndrome","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"study_design","value":"Guideline","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"Recommendations against routine MRD monitoring or maintenance reflect insufficient evidence, not proof of no benefit.","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"Some donor-source comparisons (especially haploidentical) derive from small cohorts and may not generalize.","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"This is a consensus guideline synthesizing heterogeneous studies rather than a single trial.","value_numeric":null}],"summaries":{"what_studied":"Expert consensus guidance from the EBMT PH&G Committee on when and how to use allogeneic haematopoietic cell transplantation for cutaneous T‑cell lymphomas (mycosis fungoides and Sézary syndrome), covering referral criteria, timing/bridging, donor selection, conditioning/GVHD prophylaxis, and post‑transplant care.","key_result":"In the CUTALLO propensity‑matched prospective study (n=99), allo‑HCT prolonged PFS to 9.0 months vs 3.0 months with conventional therapy (HR 0.38, 95% CI 0.21–0.69; p<0.0001). Historical/pooled benchmarks for allo‑HCT show 5‑year OS 38% and PFS 26% (EBMT registry), and OS 51% at 1 year and 40% at 3 years with PFS 42% at 1 year and 33% at 3 years (meta‑analysis).","limitations":"Recommendations rest largely on retrospective series, registry analyses, and small prospective cohorts, with heterogeneous conditioning, donor sources, and peri‑transplant practices. Evidence for haploidentical donors, modern GVHD prophylaxis (e.g., PTCy), MRD monitoring, and maintenance strategies remains limited or inconclusive.","practice_takeaway":"Refer high‑risk MF/SS early; aim for CR or deep response (VGPR or mSWAT <10) before RIC allo‑HCT, prefer MRD/MUD donors, and observe a 6‑week washout after pre‑HCT mogamulizumab. Manage relapse with immunosuppression taper and DLI, adding site‑directed therapy or TSEB as indicated; routine post‑HCT MRD monitoring or maintenance is not recommended."}}],"initialOffset":9,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Allogeneic Hematopoietic Cell Transplantation"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Allogeneic Hematopoietic Cell Transplantation"}}}]]

Papers